Oral News and Research

RSS

High Court to hear arguments today in case mixing religious freedoms and health law's birth control coverage requirement

The case, which touches various politically charged issues, could have implications beyond the health law's birth control coverage requirement.

26 Mar 2014

High court hears arguments regarding the birth control coverage mandate

Justices appeared divided over this case, which involves both issues of religious freedoms and a provision of the health overhaul.

26 Mar 2014

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

26 Mar 2014

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology.

26 Mar 2014

Vigilant announces completion of $2 million oversubscribed Series A financing

Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.

25 Mar 2014

First Edition: March 25, 2014

Today's early morning highlights from the major news organizations, including stories previewing today's Supreme Court action regarding the health law's contraception coverage mandate.

25 Mar 2014

Agios initiates AG-120 Phase 1 study to evaluate advanced solid tumors with IDH1 mutation

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.

25 Mar 2014

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.

25 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014

CUMC researchers devise new system for classifying periodontal disease

Researchers at Columbia University Medical Center have devised a new system for classifying periodontal disease based on the genetic signature of affected tissue, rather than on clinical signs and symptoms. The new classification system, the first of its kind, may allow for earlier detection and more individualized treatment of severe periodontitis, before loss of teeth and supportive bone occurs.

24 Mar 2014

Viewpoints: Predictions of rising premiums in 2015; anniversary of health law

No one challenges reality like Kathleen Sebelius, who assured the world on Sept. 30, 2013 that the Affordable Care Act website would be open for business the next day. "We're very excited about tomorrow," Sebelius said. "Shutdown or no shutdown, we're ready to go."

24 Mar 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

21 Mar 2014

Viewpoints: Romneycare and cutting workers; Fla.'s surprising ruling on malpractice reform

Health reform in Massachusetts in 2006 did not cause many workers to have their work hours cut, but that is no comfort for those workers nationwide who will begin to experience this side effect of the federal Affordable Care Act (Casey B. Mulligan, 3/19).

21 Mar 2014

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today provided a clinical update on its lead antibiotic candidate, eravacycline, and its Phase 3 global clinical program IGNITE (Investigating Gram-negative Infections Treated with Eravacycline).

21 Mar 2014

High Court to hear religious freedom challenge to contraceptive mandate

The health law returns to the Supreme Court next week when justices consider a challenge by two companies seeking relief from the contraceptive coverage requirement.

21 Mar 2014

Study: Infections caused by antibiotic-resistant bacteria are on rise in U.S. children

Infections caused by a concerning type of antibiotic-resistant bacteria are on the rise in U.S. children, according to a new study published in the Journal of the Pediatric Infectious Diseases Society and available online.

20 Mar 2014

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.

19 Mar 2014

New case study reveals how to safely switch between anticoagulants for stroke prevention

With the availability of newer oral anticoagulants, the latest online case study from NPS MedicineWise helps health professionals navigate this changing area and understand the range of treatment options for managing stroke prevention in people with non-valvular atrial fibrillation.

18 Mar 2014

Oral News and Research

High Court to hear arguments today in case mixing religious freedoms and health law's birth control coverage requirement

High court hears arguments regarding the birth control coverage mandate

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Vigilant announces completion of $2 million oversubscribed Series A financing

First Edition: March 25, 2014

Agios initiates AG-120 Phase 1 study to evaluate advanced solid tumors with IDH1 mutation

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

CUMC researchers devise new system for classifying periodontal disease

Viewpoints: Predictions of rising premiums in 2015; anniversary of health law

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

Viewpoints: Romneycare and cutting workers; Fla.'s surprising ruling on malpractice reform

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

High Court to hear religious freedom challenge to contraceptive mandate

Study: Infections caused by antibiotic-resistant bacteria are on rise in U.S. children

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

New case study reveals how to safely switch between anticoagulants for stroke prevention

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News